ResMed (RMD): The stock had negative money flow to the tune of ($8.33 million) on Friday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $8.34 million, whereas, the outflow of money on downticks was $16.67 million and the ratio between the two was 0.5. The block trade had a negative net money flow of ($7.22 million). On the other hand, downticks amounted to $7.22 million of the traded value, which shows distribution in the stock by traders. ResMed (RMD) closed with marginal gains of 4 cents to end the day at $65.93, an increase of 0.06% over the previous days close. The stock recorded 1.74% for the week.
ResMed (RMD) : 7 Wall Street analysts covering ResMed (RMD) believe that the average level the stock could reach for the short term is $56.91. The maximum price target given is $65 and the minimum target for short term is around $44, hence the standard deviation is calculated at $6.98.
ResMed (NYSE:RMD): stock turned positive on Friday. Though the stock opened at $65.86, the bulls momentum made the stock top out at $66.11 level for the day. The stock recorded a low of $65.56 and closed the trading day at $65.93, in the green by 0.06%. The total traded volume for the day was 983,838. The stock had closed at $65.89 in the previous days trading.
In a related news, Farrell Michael J., officer (Chief Executive Officer) of Resmed Inc, unloaded 5,975 shares at an average price of $65.03 on July 15, 2016. The total amount of the transaction was worth $388,554, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.